The Effect of Secretome Hypoxia Mesenchymal Stem Cells (SH-MSCs) in Reducing P65 and TNF-Α Gene Expression in Polycystic Ovary Syndrome

Abstract

Polycystic Ovary Syndrome (PCOS) is an endocrine and metabolic syndrome characterized by a chronic inflammation and an increase of androgen production in ovarian theca cells.1 The expression of the p65 gene and TNF-α was found to be intracellular inflammation markers in PCOS patients. Previous studies have indicated that the Secretome of hypoxia mesenchymal stem cells (SH-MSCs) has anti-inflammatory properties and is widely reported to be effective in treating various diseases. An experimental study by using the Post Test Only Control Group Design method. This study involved 24 female wistar rats divided into 4 groups. Group K1 consisted of healthy rats, K2 PCOS rats without any treatment, K3 PCOS rats treated with 200μL dose of SH-MSCs, and K4 PCOS rats treated with 400μL dose of SH-MSCs. On the 33rd day, the rats underwent an examination of the p65 and TNF-α gene expression. The result of Shapiro-Wilk test and Levene test indicated that the data were normally distributed and homogenous. In One-Way ANOVA test, groups K III and K IV of PCOS rats showed significantly lower changes in the expression of the p65 and TNF-α genes compared to the control group (p<0.05). The result of Kruskal-Wallis test and Mann-Whitney test showed significant differences in TNF-α gene expression among the groups (p <0.05). While, the post hoc Tamhane test showed significant differences in p65 gene expression among the groups (p<0.05). SH-MSCs given at a dose of 200 µL/kgBW and 400 µL/kgBW had an effect in reducing the expression of the p65 gene and TNF-α gene on female wistar rats of PCOS model.